George Cotsarelis of Follica predicts product launch as another Five Years Away, with trials in two to three.

Right on the heels of previous funding, Follica has just announced the completion of a second round of funding, grabbing 11 million USD and G. Kirk Raab, ex-CEO of biotech giant Genentech as a chairman. Follica CEO Daphne Zohar heads up the publicity with an overview on Xconomy.com: “Our research has been progressing in a very positive way. We have had significant interest from the venture community and while we just closed the Series A round a few months ago …

Video from MSNBC showing Follica’s co-founder, George Cotsarelis, predicting a market release “within a few years” under “perfect” circumstances. It is also confirmed that human trials should begin “within the next year or two”.